BIO-TECHNE Corp
No SEC Form 4 filings for $TECH in the last 30 days.
See all $TECH insider activity →Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 sales of $321.2 million, up 1.3% year on year and 2% above Wall Street’s revenue estimate. Non-GAAP adjusted EPS was $0.52, near consensus and down from $0.53 a year earlier. Analysts expect full-year EPS to rise from $1.93 to $2.04.
BIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tech-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Techne Releases Fourth Quarter Fiscal 2026 Results Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter
Conestoga Capital Advisors’ Q2 2026 investor letter says small-cap sentiment improved, citing strong Russell 2000 and Russell 2000 Growth results, though leadership was uneven. The letter highlights Bio-Techne (NASDAQ:TECH) as a performance contributor, noting its $72 close on Aug. 5, 2026, and a 43.57% 52-week gain. It says improving academic funding and large pharma strength helped, and that Bio-Techne agreed to be acquired by Merck KGaA (MRK-GR).
Over the past 7 days, alphai's AI scored 3 news stories mentioning TECH (BIO-TECHNE Corp). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent TECH coverage spans mergers & acquisitions, earnings and technology.
A modest revenue beat with contracting margins suggests limited upside unless investors focus on durability of organic growth.
The 8-K combines an earnings datapoint with a confirmed takeout price, shifting the stock’s primary driver to deal completion risk and any post-earnings updates.
The article frames TECH’s near-term outlook as improving as academic funding and large-pharma demand offset emerging-biotech weakness, alongside a disclosed acquisition agreement.
Pre-earnings positioning likely hinges on whether Q4 EPS and revenue land near flat-to-slightly down consensus, with segment volatility risk flagged.
Product portfolio expansion for R&D Systems AI-Engineered Designer Proteins could modestly support demand expectations, but the release is promotional without financial guidance.
alphai scores every news story that mentions TECH with an AI model for sentiment and relevance, and aggregates insider trades from BIO-TECHNE Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 sales of $321.2 million, up 1.3% year on year and 2% above Wall Street’s revenue estimate. Non-GAAP adjusted EPS was $0.52, near consensus and down from $0.53 a year earlier. Analysts expect full-year EPS to rise from $1.93 to $2.04.
4 min readBIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tech-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Techne Releases Fourth Quarter Fiscal 2026 Results Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter
6 min readConestoga Capital Advisors’ Q2 2026 investor letter says small-cap sentiment improved, citing strong Russell 2000 and Russell 2000 Growth results, though leadership was uneven. The letter highlights Bio-Techne (NASDAQ:TECH) as a performance contributor, noting its $72 close on Aug. 5, 2026, and a 43.57% 52-week gain. It says improving academic funding and large pharma strength helped, and that Bio-Techne agreed to be acquired by Merck KGaA (MRK-GR).
4 min readBio-Techne (TECH) is set to report fiscal Q4 2026 results on Aug. 5. In its prior quarter, adjusted EPS was 53 cents, missing the Zacks Consensus by 3.64%. Revenue is forecast at $317.2 million and EPS at 52 cents. The article also notes Merck KGaA agreed to acquire Bio-Techne for $73 per share.
6 min readBio-Techne (NASDAQ: TECH) said it launched expanded R&D Systems AI-Engineered Designer Protein portfolio additions, including heat-stable FGF-4, FGF-7, FGF-8b, IL-3 heat stable, and IL-15 hyperactive proteins. The company said the platform aims to improve stability, activity, and reproducibility for advanced cell culture and cell therapy workflows. Bio-Techne reported fiscal 2025 net sales over $1.2 billion.
4 min readMerck KGaA (Germany) agreed to buy Minnesota-based Bio-Techne in an $11.3 billion deal, its biggest acquisition in over 10 years, as it expands under CEO Kai Beckmann. Merck expects about $159 million in cost savings over three years. The report says the move would strengthen Merck in drug discovery and gene therapy; Bio-Techne shares rose nearly 20% on the Nasdaq.
6 min readBio-Techne (TECH) shares rose 20.08% to close at $70.70 after the company said it entered a definitive agreement to be acquired by Merck for an all-cash $11.3 billion. Bio-Techne will sell shares at $73 each, a 24% premium to Wednesday’s close. The deal is expected to close late 2026 or early 2027, pending regulatory and shareholder approvals.
3 min readBio-Techne (TECH) surged 20.02% to close at $70.67 after Merck KGaA announced a $73-per-share cash acquisition offer, according to the report. Trading volume was 51.3M shares, about 1,378% above its three-month average. The S&P 500 edged down 0.01% and the Nasdaq fell 0.46%.
4 min readU.S. stocks closed mixed: the S&P 500 fell to a two-week low while the Dow hit a record. Apple slid over 6% after raising prices on Macs, iPads, home devices and Vision Pro to offset memory-chip and storage shortages. Chipmakers rallied, led by Micron up 15% after forecasting Q4 revenue of $50B.
7 min readBIO-TECHNE Corp (TECH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm AGREEMENT AND PLAN OF MERGER BIO-TECHNE CORPORATION 8-K Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among MERCK KGAA, DARMSTADT, GERMANY, EMD HOLDINGS NEWCO, INC. and BIO-TECHNE CORPORATION Dated as of June 25, 2026 TABLE OF CONTENTS ARTICLE I TH
4 min read
